You used to enjoy things. Now nothing feels good. Your genes may explain why.

After a nerve cell releases serotonin into the space between neurons, a transporter protein grabs it and pulls it back in so the brain can reuse it. SLC6A4 codes for that transporter. It is the recycling system for the neurotransmitter that makes mood stable and pleasure accessible. The longer serotonin stays in the synapse, the longer the mood signal lasts.

Here is the problem: the 5-HTTLPR short allele variant of SLC6A4, carried by roughly 40 percent of the population, codes for a less efficient transporter. That means serotonin is pulled back and recycled too quickly, shortening the window in which that mood signal can be felt. Worse, the short allele is also associated with reduced transporter expression overall, meaning fewer recycling vehicles doing the work. People with the short allele experience more dramatic serotonin dips between nerve impulses, which translates to less stable mood, more anxiety reactivity, and less ability to sustain the neurochemical state that allows pleasure.

You might notice this as mood swings, as a fragility to your emotional state, as needing social connection or stimulation constantly to feel okay, or as an inability to sit still with positive feelings without them collapsing. Anhedonia with the short allele often feels like the joy is there but it evaporates too fast. You taste the pleasure and then it is gone, leaving behind a kind of yearning.

Dopamine is the neurotransmitter of reward, motivation, focus, and pleasure. COMT is the enzyme that breaks it down. If COMT works too slowly, dopamine accumulates and you feel overstimulated, scattered, anxious. If COMT works too fast, dopamine clears out of your synapses too quickly, and you lose the pleasure signal before you can feel it.

The Val158Met variant is the most studied. People with the Met version (slow COMT) carry about 40 to 50 percent less enzyme activity. But there is also a fast version that some people carry, where COMT clears dopamine almost too efficiently. If you are a fast COMT clearer, dopamine drops out of your synapse rapidly, which can create a kind of emotional bluntness, an inability to sustain pleasure, and a constant need for stimulation or novelty to feel anything at all. Fast COMT is often associated with anhedonia that feels like low motivation and flatness rather than sadness.

You might notice this as an inability to feel satisfied, as always needing the next thing, the next achievement, the next stimulus. Pleasures that worked last week do not work this week. Food does not taste good for long. Sex feels mechanical. Nothing sticks. You are not depressed in the traditional sense, but you are not alive either. You are watching the world from behind glass.

Brain-derived neurotrophic factor is a protein that keeps brain cells alive, helps them grow new connections, and allows your brain to change and adapt in response to experience. Without adequate BDNF, your brain gets stuck in old patterns. Antidepressants work partly by increasing BDNF; therapy works by leveraging neuroplasticity that BDNF enables. If you do not have enough BDNF available, even the right treatment struggles to work.

The Val66Met variant reduces BDNF secretion, particularly in response to stress or activity. People carrying the Met allele (about 30 percent of the population) produce less BDNF from the outset, and their BDNF does not increase as robustly when they exercise, learn, or undergo treatment. If you have low BDNF variants, your brain has less capacity to change its wiring in response to antidepressants, therapy, or even positive lifestyle changes. This is a major reason why some people do therapy for years and feel stuck, why antidepressants help but never fully resolve anhedonia, why your brain feels rigid and unable to shift out of flatness.

You might experience this as a sense of being trapped, of trying everything and nothing working, of a kind of neurological inertia. Pleasure was not accessible before and your brain cannot seem to rewire toward pleasure even with intervention. Hope itself becomes hard to sustain because you have learned that change does not happen.

Before your brain can recycle serotonin or respond to it, the brain has to make it first. Tryptophan hydroxylase 2 (TPH2) is the rate-limiting enzyme in that process. It converts tryptophan, an amino acid you eat, into 5-hydroxytryptophan (5-HTP), which then becomes serotonin. If TPH2 is slow or inefficient, your brain is making serotonin from scratch more slowly than it needs to, no matter how much tryptophan you consume.

TPH2 variants are less common than variants in SLC6A4 or COMT, but they affect roughly 20 percent of the population. People with reduced TPH2 activity produce less serotonin baseline. Their brain starts with a deficit. If you have a TPH2 variant that reduces activity, you may have had low mood, anxiety, and blunted pleasure your entire life, even as a child, in a way that never quite responded to normal amounts of serotonin support.

You might recognize this as a lifelong mood fragility, as never having felt quite happy even in objectively good circumstances, as a sense that joy was never really available to you, as anhedonia that goes back to childhood. SSRIs help somewhat because they preserve the small amount of serotonin you do make, but you might always feel a ceiling on how good you can feel because the raw material is simply not being made fast enough.

After serotonin, dopamine, and norepinephrine have done their job in the synapse, an enzyme called monoamine oxidase A (MAOA) breaks them down so they can be cleared. This is necessary and normal. But if MAOA works slowly, these neurotransmitters linger in the synapse. They accumulate. Your brain swings between periods of high levels and rapid drops.

The MAOA-L (low-activity) variant is carried by roughly 30 to 40 percent of males (females have two X chromosomes so the genetics are more complex). People with MAOA-L have slower breakdown of dopamine, serotonin, and norepinephrine, which means more time these chemicals spend active, but also more volatility as they spike and crash. MAOA-L is associated with heightened emotional reactivity, quicker triggering of stress response, and a kind of neurochemical instability where your mood and motivation fluctuate unpredictably.

You might experience this as mood swings that feel neurochemical rather than situational, as irritability or sudden rage, as anxiety that spikes without warning, and as difficulty sustaining pleasure because the dopamine and serotonin levels are fluctuating rather than steady. Anhedonia with MAOA-L can feel like emotional volatility punctuated by flatness.

When you experience stress, your body releases cortisol. Cortisol is supposed to be a temporary mobilizer, but then it should drop back down. FKBP5 is a protein that helps your brain’s glucocorticoid receptors turn off the cortisol signal. If FKBP5 is not functioning optimally, the stress signal does not turn off cleanly. Cortisol lingers in your bloodstream and brain longer than it should.

The rs1360780 variant, carried by roughly 30 percent of the population, impairs glucocorticoid receptor sensitivity. That means your brain does not respond well to cortisol’s signal to calm down. Even after the stressor is gone, your cortisol stays elevated, and elevated cortisol is a direct suppressor of dopamine and serotonin. Your brain is essentially stuck in a low-level stress state, which directly erodes the neurochemical conditions necessary for pleasure.

You might recognize this as a sense of never quite relaxing, of always being on edge, of feeling safe but not really feeling safe, of a baseline anxiety that does not go away even when nothing bad is happening. Pleasure is hard to access because the stress system is suppressing it. It is not that pleasure is absent; it is that the stress chemicals are drowning it out.